Yan Qi, Prasla Sanaa, Carlisle Daniel C, Rajesh Aashish, Treffalls John, Davies Mark G
Division of Vascular and Endovascular Surgery, University of Texas Health at San Antonio, San Antonio, TX; Department of Surgery, University of Texas Health at San Antonio, San Antonio, TX; South Texas Center for Vascular Care, South Texas Medical Center, San Antonio, TX.
Department of Surgery, University of Texas Health at San Antonio, San Antonio, TX.
Ann Vasc Surg. 2022 Apr;81:1-21. doi: 10.1016/j.avsg.2021.10.059. Epub 2021 Dec 7.
Venous arterialization is an upcoming and novel alternative in chronic limb threatening ischemia (CLTI) patients in the absence of standard revascularization options. The aim of this study is to systematically review and analyze outcomes of venous arterialization.
A systematic literature search was performed in 5 databases using the PRISMA methodology. Inclusion criteria were English language original research papers on CLTI patients treated with venous arterialization.
absence of CLTI due to atherosclerosis, duplicate study or reporting of patients, meeting abstract only. Quality and risk of bias were evaluated. Meta-analysis was performed using random effects model on articles that have a sample size of equal or greater than 10.
Twelve studies included 442 patients that underwent treatment for 445 limbs (374 patients and 377 limbs underwent venous arterialization while remainder underwent traditional bypass and served as control subjects). Average age was 66 [18 studies, range 37 -91 years], 68% were male [271/366, 15 studies] and 67% diabetic [271/406, 16 studies]). Most limbs (88%, 352/398, 16 studies) had tissue loss. Pooled 30-day mortality was 3.7% (95%-confidence interval [CI] 0.8 -6.6%), 30-day morbidity was 15.5% (95%-CI 3.2 -27.8%), 30-day major adverse cardiovascular event was 5.2% (95%-CI 1.7 -8.6%) and 30-day major adverse limb event was 16.7% (95%-CI 1.5 -31.9%). Pooled 1-year limb-salvage rate was 79.0% (95%-CI 68.7 -90.7) and 1-year survival rate was 85.7% (95%-CI 76.2 -96.4). Studies quality varied significantly across studies.
Venous arterialization has an acceptable a 1-year limb salvage rate of 79%, however, this is based on low levels of evidence. More randomized controlled trials or high-quality cohort studies are needed to further define the effectiveness of this procedure for CLTI.
在没有标准血运重建方案的情况下,静脉动脉化是治疗慢性肢体威胁性缺血(CLTI)患者的一种新兴且新颖的替代方法。本研究的目的是系统回顾和分析静脉动脉化的治疗结果。
采用PRISMA方法在5个数据库中进行系统的文献检索。纳入标准为关于接受静脉动脉化治疗的CLTI患者的英文原创研究论文。
因动脉粥样硬化导致的非CLTI、重复研究或患者报告、仅会议摘要。评估质量和偏倚风险。对样本量等于或大于10的文章使用随机效应模型进行荟萃分析。
12项研究纳入了442例接受445条肢体治疗的患者(374例患者和377条肢体接受了静脉动脉化治疗,其余接受传统旁路手术并作为对照)。平均年龄为66岁[18项研究,范围37 - 91岁],68%为男性[271/366,15项研究],67%为糖尿病患者[271/406,16项研究])。大多数肢体(88%,352/398,16项研究)存在组织缺损。汇总的30天死亡率为3.7%(95%置信区间[CI] 0.8 - 6.6%),30天发病率为15.5%(95%CI 3.2 - 27.8%),30天主要不良心血管事件为5.2%(95%CI 1.7 - 8.6%),30天主要不良肢体事件为16.7%(95%CI 1.5 - 31.9%)。汇总的1年肢体挽救率为79.0%(95%CI 68.7 - 90.7),1年生存率为85.7%(95%CI 76.2 - 96.4)。各研究的质量差异显著。
静脉动脉化的1年肢体挽救率为79%,可以接受,然而,这是基于低水平的证据。需要更多的随机对照试验或高质量队列研究来进一步明确该手术对CLTI的有效性。